<DOC>
	<DOCNO>NCT01124149</DOCNO>
	<brief_summary>This study design evaluate subject achieve complete remission 8 week acute therapy MMX mesalamine/mesalazine 4.8g/day give QD well long-term outcome remain remission longer compare subject demonstrate partial remission acute therapy MMX mesalamine/mesalazine 4.8g/day give QD . Therefore , subject achieve either complete partial remission enter 12-month maintenance phase , receive MMX mesalamine/mesalazine 2.4g/day give QD . Remission status 2 group evaluate compare end 12-month maintenance period . The data obtain study provide scientifically meaningful information demonstrate achieve complete remission ( clinical endoscopic remission ) important good long-term prognosis , current paradigm symptomatic treatment appropriate .</brief_summary>
	<brief_title>Ability Maintain Achieve Clinical Endoscopic Remission With MMX Mesalamine Once Daily Adults With Ulcerative Colitis</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Mesalamine</mesh_term>
	<criteria>1 . Adults age 18 old 2 . Male , nonpregnant , nonlactating female agree comply applicable contraceptive requirement protocol 3 . Diagnosis active mild moderate UC ( acute flare newly diagnose ) 4 . Stable maintenance therapy 5ASA less equal 3.2 g/day ( exclude MMX mesalamine/mesalazine ) , 5ASA take onset acute flare . 1 . Severe UC 2 . Acute flare onset great &gt; 6 week prior baseline maintenance therapy . There limit onset flare prior baseline flare untreated . 3 . Acute flare maintenance MMX mesalamine/mesalazine ( Lialda , Mezavant , Mezavant XL , Mezavant LP ) 4 . Unsuccessfully treated current acute flare use steroid 5ASA dos &gt; 3.2 g/day 5 . Acute flare 5ASA maintenance therapy &gt; 3.2 g/day 6 . Systemic rectal steroid use within 4 week prior screen immunosuppressant within last 6 week prior screen 7 . History biologic ( antiTNF agent ) use 8 . Antibiotic use repeat use ( &gt; 3 consecutive day use dos prescribe overthecounter dose ) antiinflammatory drug , include nonsteroidal antiinflammatory drug aspirin , COX2 inhibitor ibuprofen , within 7 day prior screen . However , prophylactic use stable dose aspirin 325mg/day cardiac disease permit 9 . Current recurrent disease , UC , could affect colon , action , absorption , disposition IMP , clinical laboratory assessment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>